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Clinical usage of cannabinoids in chronic pain states is limited by their central side effects and the pharmacodynamic tolerance that sets
in after repeated dosage. Analgesic tolerance to cannabinoids in vivo could be caused by agonist-induced downregulation and intracel-
lular trafficking of cannabinoid receptors, but little is known about the molecular mechanisms involved. We show here that the type 1
cannabinoid receptor (CB1) interacts physically with G-protein-associated sorting protein 1 (GASP1), a protein that sorts receptors in
lysosomal compartments destined for degradation. CB1–GASP1 interaction was observed to be required for agonist-induced downregu-
lation of CB1 in spinal neurons ex vivo as well as in vivo. Importantly, uncoupling CB1 from GASP1 in mice in vivo abrogated tolerance
toward cannabinoid-induced analgesia. These results suggest that GASP1 is a key regulator of the fate of CB1 after agonist exposure in the
nervous system and critically determines analgesic tolerance to cannabinoids.
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Introduction
The endocannabinoid system constitutes an important biological
defense mechanism against acute and pathological pain (Calig-
nano et al., 1998; Rice, 2001). Neural effects of cannabinoids are
primarilymediated by type 1 cannabinoid receptors (CB1), which
are Gi/o-coupled G-protein-coupled receptors (GPCRs) (Rice,
2001;Walker andHohmann, 2005;Mackie, 2006). Cannabinoids
effectively attenuate nociceptive hypersensitivity in animal mod-
els of chronic pain and have shown promise in preclinical and
clinical studies (Rice, 2001;Walker andHohmann, 2005;Mackie,
2006).
The clinical usage of cannabinoids is limited because of two
major reasons. First, cannabinoids cause central side effects, such
as sedation, temporary memory impairment, and psychotropic
effects (Iverson, 2003; Marsicano and Lutz, 2006). Second, the
analgesic efficacy of cannabinoids progressively decreases during
repeated usage, a phenomenon referred to as tolerance (DeVry et
al., 2004; Martin et al., 2004; Gonzalez et al., 2005; Rubino et al.,
2005).
Pharmacodynamic tolerance to drugs is a result of adaptive,
use-dependent changes in cellular targets of drugs after long-
term or frequent exposure (von Zastrow, 2003). A key determi-
nant of this process is the activation status and the number of
receptors expressed at the cell surface. Internalization after ago-
nist exposure constitutes a common feature of numerous GPCRs
(Tsao and von Zastrow, 2000). During internalization, some
GPCRs rapidly recycle back to the cell membrane, whereas others
are sorted into lysosomes and degraded, thereby decreasing func-
tional cell surface receptors (Tsao and von Zastrow, 2000; von
Zastrow, 2003). Lysosomal degradation has therefore been pos-
tulated to lead to tolerance.
Recently, a protein called G-protein receptor associated sort-
ing protein (GASP) was discovered to mediate the sorting of
-opioid receptors to lysosomes (Whistler et al., 2002). Subse-
quent studies revealed that GASP (now called GASP1) is a mem-
ber of a novel family, consisting of 10 members (GASP-1 to
GASP-10) (Simonin et al., 2004), which can physically associate
with a variety of GPCRs (Heydorn et al., 2004; Simonin et al.,
2004; Bartlett et al., 2005).
So far, several studies have addressed the trafficking of canna-
binoid receptors, and the Rab5 GTPase and dynamin have been
demonstrated recently to play a role in constitutive endocytosis
and axonal targeting of CB1, respectively (Leterrier et al., 2004,
2006; McDonald et al., 2007). However, the molecular mecha-
nisms governing the intracellular fate of cannabinoid receptors
during prolonged agonist exposure remain unclear. The intracel-
lular C-terminal tail of CB1 has been identified as a region critical
in agonist-induced internalization (Hsieh et al., 1999; Jin et al.,
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1999) and could serve as an important avenue for intracellular
protein–protein interactions.
We show here that GASP1 interacts with CB1 in the nervous
system in which it mediates the sorting of CB1 into lysosomal
compartments during protracted agonist exposure. Disruption
of the CB1–GASP1 interaction via a dominant-negative mutant
version ofGASP reduces agonist-induced downregulation of CB1
in spinal neurons in culture as well as in vivo. Importantly, the
CB1–GASP1 interaction is required for analgesic tolerance to
cannabinoids. Thus, this study provides the first direct link be-
tween molecular mechanisms underlying CB1 receptor traffick-
ing and analgesic tolerance to cannabinoids in vivo.
Materials andMethods
Plasmids and constructs. The constructs expressing N-terminally hemag-
glutinin (HA)-tagged human CB1 cDNA as well as N-terminally HA-
tagged V460Z (Z: stop codon) and V464Z mutants of CB1 have been
described previously (Hsieh et al., 1999). Similarly, constructs expressing
green fluorescent protein (GFP) N-terminally in frame with the second
codon of human GASP (GFP–GASP) or with the C-terminal 467 amino
acids of GASP (GFP–cGASP) and N-terminally HA-tagged cGASP have
been described previously (Whistler et al., 2002).
Generation of a stable cell line expressing enhanced GFP–CB1. Coding
sequence of theCB1 receptorwas amplified by reverse transcription-PCR
from mouse brain. To avoid potential removal of the enhanced GFP
(EGFP) tag from theN terminus at any unidentified signal peptide cleav-
age site, the first 25 N-terminal amino acids were excluded from the
amplicon. The remaining fragment was cloned in frame behind EGFP,
and the fusion construct was sequenced to confirm lack of mutations.
Human embryonic kidney 293 (HEK293) cells were maintained accord-
ing to routine protocols, and 10 g of the plasmid was transfected using
calcium chloride (2 M). Drug-resistant colonies were selected using G418
(200 g/ml) after 12 d of treatment, and clones expressing EGFP–CB1 at
low to moderate levels were propagated further. These clones were
picked up and propagated for experimental analysis.
Immunoprecipitation and Western blot analysis. HEK293 cells were
scraped and lysed in 500 l of TNE buffer (10 mM Tris, pH 7.5, 0.5 M
NaCl, 5 mM EDTA, and 0.1% Triton X-100). with protease inhibitors
48 h after calcium phosphate transfection of the indicated constructs.
Lysis proceeded for 20 min at 4°C, and lysates were then centrifuged for
10 min at 13,000 rpm in ice-cold tabletop centrifuge. Cleared lysate was
then incubated with the indicated antibody. Rabbit anti-CB1 (Cayman
Chemical, Ann Arbor,MI), rat anti-HA (Roche, Basal, Switzerland), and
rabbit anti-GFP (Chemicon, Temecula, CA) antibodies were used. The
antibody–antigen complexes were isolated by binding to 30l of protein
A/G Sepharose beads for 3–4 h at 4°C. Beads were then pelleted at 10,000
rpm for 30–40 s at 4°C and washed four times with ice cold TNE buffer
with protease inhibitors. Precipitated proteins were then boiled in SDS
sample buffer for 3 min at 95°C and analyzed on 10% SDS-PAGE gels.
Goat anti-rabbit HRP and goat anti-rat HRP antibodies were used for
Western blotting following standard protocols. For coimmunoprecipi-
tation from cultured spinal neurons, neurons were pooled from 12–14
10 cm plates in total volume of 1.5 ml of TNE lysis buffer with protease
inhibitors and processed further as described for HEK293 cells.
Immunoprecipitation on rat brain lysates. Brains from adultWistar rats
were dissected, washed with PBS, and homogenized in IPB buffer (0.1%
Triton X-100, 150 mMNaCl, 25 mM KCl, 10 mM Tris-HCl, pH 7.4, and 1
mM CaCl2) containing Complete, Mini, and EDTA-free Protease inhib-
itor tablets (Roche) and centrifuged at 1500 rpm for 15 min at 4°C.
Supernatant was centrifuged at 60,000 rpm for 20 min. The pellet was
resuspended in IPB buffer containing 1% Triton X-100 and protease
inhibitors and preincubated for 2 h at 4°C with protein A/G Plus Sepha-
rose beads (Santa Cruz Biotechnology, Santa Cruz, CA). Beads were
removed by centrifugation, and the supernatant was incubated with the
CB1 antibody (1:200; Chemicon) or GFP antibody (1:1000; Chemicon)
overnight, followed by an additional 2 h incubation with protein A/G
Plus Sepharose beads. Beads were washed three times with IPB buffer
containing 1% Triton X-100. Subsequently, sucrose cushioning was per-
formed twice by adding IPB buffer and 1 M sucrose to the bottom of the
vial. Beads were next washed twice with 1% Triton X-100/IPB and twice
with 10 mM Tris HCl. Beads were then incubated with PNGase F for 1 h
at 37°C and CB1 receptor blocking peptide (Cayman Chemical). Beads
were removed by centrifugation, and the supernatant was boiled for 5
minwith 4 SDS sample buffer (0.03ml; 4 SDS sample buffer: 286mM
Tris-HCl, pH 6.8, 5.7% SDS, 10 mM EDTA, 28% glycerol, 3.5 mg/ml
bromophenol blue, and 4.7 mg/ml -mercaptoethanol) and loaded on
10% SDS-polyacrylamide gel. Blots were divided in upper and lower
parts and hybridized with anti-GASP antibody (1:1000) (Bartlett et al.,
2005) or CB1 antibody (1:1000; Chemicon) in 8% blocking dry milk
using anti-rabbit HRP secondary antibody (1:4000) in 8% blocking dry
milk.
Analysis of CB1 trafficking in HEK293 cells. HEK293 cells stably ex-
pressing GFP–CB1 were cultured with G418 in complete DMEM on
poly-L-lysine-coated glass coverslips. In some experiments, cells were
transfected using Lipofectamine. At 40 h after transfection, cells were
incubated with cycloheximide (40 M) in DMEMwithout serum for 1 h
at 37°C.WIN 55,212-2 [R-()-(2,3-dihydro-5-methyl-3-[(4-morpholinyl)
methyl]pyrrolo[1,2,3-de]-1,4- benzoxazin-6-yl)(1-naphthalenyl) meth-
anonemonomethanesulfonate] (WIN) (100 nM) or vehicle was added in
DMEM, and cells were incubated for varying periods of time (5, 15, 30,
45, 60, and 90 min), washed, and fixed with 4% paraformaldehyde
(PFA). When recycling was to be tested, cells that had been treated with
agonist were washed in ice-cold PBS, and cells were incubated with fresh
DMEM for an additional hour, after which cells were washed with PBS
and fixed in 4% PFA for 5 min at 4°C. Cells were directly analyzed
microscopically or processed for immunofluorescence with rat anti-HA
antibody (Roche) or Lyso-tracker dye (1: 20,000 dilution; BD PharMin-
gen, San Diego, CA) using standard protocols.
Alkaline phosphatase-based surface expression assay. Sixty hours after
transfection with the indicated constructs, COS7 cells were incubated
with cycloheximide (40M) inDMEM for 1 h. Cells were incubated with
WIN 55,212-2 (100 nM) or vehicle as described above and then treated
with primary anti-FLAGM1 antibody (Sigma, St. Louis, MO) in DMEM
containing 5% horse serum at 4°C for 3 h. Cells were washed, fixed with
4% PFA for 10 min, and incubated for 30 min with the AP-linked anti-
mouse antibody at room temperature, followed by washing with HBBS.
Cells were then incubatedwith the AP assay reagent A at 37°C to visualize
AP activity as described previously (Swiercz et al., 2004). The absorbance
was measured at 605 nm.
Biotin protection degradation assay. HEK 293 cells stably expressing
CB1 were grown to confluency in poly-D-lysine-pretreated 10 cm plates.
Before the experiment, a subset of plates were pretreated with the pro-
tease inhibitors 200 M chloroquine, 100 M leupeptin, and 50 M
NH4Cl (Sigma) dissolved in water at 37°C for 60min. Next, all cells were
treated with 3 g/ml disulfide-cleavable biotin (Pierce, Rockford, IL) at
4°C for 30min,washed inTBS (inmM: 137NaCl, 25Tris-base, 3KCl, and
1 CaCl2) placed in DMEM with or without presence of protease inhibi-
tors and treated with ligand (1 nM to 1 M WIN 55,212-2) for the speci-
fied periods of time. Fresh ligand was added every 60min. All plates were
washed in PBS, and remaining cell surface biotinylated receptors were
stripped (50 mM glutathione, 0.3 M NaCl, 75 mM NaOH, and 1% fetal
bovine serum) at 4°C for 30min. All plates were then quenched in buffer
containing 9mg/ml iodoacetamide and 10mg/ml bovine serum albumin
at 4°C for 20 min, followed by cell lysis in buffer (150 mM NaCl, 25 mM
KCl, 10 mM Tris-HCl, and 0.1% Triton X-100, pH 7.4) with added pro-
tease inhibitors (Complete; Roche) and 1mg/ml iodoacetamide. Cellular
debris was removed by centrifugation at 10,000  g at 4°C for 10 min,
and lysates were immunoprecipitated with anti-FLAG M2 antibodies
linked with rabbit anti-mouse linker antibodies to Protein A Sepharose
beads at 4°C, washed extensively, and treated with PNGaseF at 37°C for
1 h. Samples were denatured in SDS sample buffer with no reducing
agent added, resolved by SDS/PAGE using 4–20% Tris–glycine precast
gels (Invitrogen, Carlsbad, CA), transferred to nitrocellulose membrane,
overlaid with streptavidin (Vectastain ABC immunoperoxidase reagent;
Vector Laboratories, Burlingame, CA), and finally developed with ECL
plus reagents (GE Healthcare, Piscataway, NJ).
Generation of adeno-associated virus virions. The C-terminal 467
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amino acids of GASP1 (cGASP1) were amplified by PCR from mouse
GASP1 cDNA (Whistler et al., 2002) and an HA tag was introduced C
terminally in frame with cGASP1. This fragment was subcloned into a
recombinant adeno-associated virus (rAAV) plasmid backbone contain-
ing the 1.1 kb cytomegalovirus enhancer/chicken -actin (CBA) pro-
moter, the woodchuck posttranscriptional regulatory element (WPRE),
and the bovine growth hormone (bGH) poly(A) (Tappe et al., 2006). The
same rAAV–CBA–WPRE–bGH backbone carrying the EGFP cDNA
(Stratagene, La Jolla, CA)was used as control. AAVchimeric vectorswere
generated using helper plasmids encoding AAV1 and AAV2 at a ratio of
1:1 as described previously (Grimm et al., 2003). The cGASP1 fragment
was also subcloned into a Semliki Forest virus (SFV) vector, and SFV
virions were generated as described in detail by Wimmer et al. (2004).
SFV virions were diluted 1:5000 in neuronal culture medium at days in
vitro (DIV) 14, and infected neurons were used for coimmunoprecipita-
tion experiments as described above at 18 h after SFV infection.
Analysis of CB1 trafficking in primary neuronal cultures of spinal cord.
Primary spinal neurons were cultured from embryonic rats at embryonic
day 14 in Neurobasal medium with B27 supplement (1:50), L-glutamine
(2 mM), and penicillin/streptomycin (1:1000) and were allowed to ma-
ture for 2–3 weeks in vitro as described in detail previously (Tappe et al.,
2006). In some experiments, cells were infected with AAV–HA–cGASP1
or AAV–EGFP (108) at DIV 7 and assayed at DIV 20. Analysis of CB1
immunoreactivity localized on the cell surface was done using a surface
labeling protocol. Cells were incubated with medium for 0–1 h (basal),
WIN 52,212-2 (1.5M) for 6, 12, 24, and 48 h, or vehicle for 6, 12, 24, and
48 h in medium at 37°C. Cells were washed with PBS/5% serum two
times for 5min and incubatedwith anti-CB1 antibody (1:100 in culturing
medium; Cayman Chemical) at 4°C for 1 h. Cells were washed for three
times for 5 min with PBS/5% serum one time with PBS at 4°C and fixed
for 10 min 4% PFA. Neurons were immunostained with anti-HA anti-
body (Roche) and anti-neurofilament 200 antibody (Chemicon) using
anti-rat FITC, anti-rabbit tetramethylrhodamine isothiocyanate
(TRITC), and anti-mouse cyanine 5 (Cy5) (all fromDianova, Hamburg,
Germany) as described previously. EGFP, FITC, TRITC, or Cy5 fluores-
cence was imaged using a laser scanning confocal microscope (TCS
AOBS; Leica, Bensheim,Germany). EGFP or FITC fluorescencewas used
to identify AAV–EGFP-infected or AAV–cGASP–HA-infected cells, re-
spectively. Then TRITC and Cy5 fluorescence was scanned in a sequen-
tial scanmode to rule out bleed-through between channels. Scanningwas
first done on spinal neurons in the absence of agonist (basal) to deter-
mine the saturation limits for fluorescent signals. The gain of the photo-
multiplier tube then remained at a constant value, which was set below
saturation limits. Neurons subjected to all of the different treatments
were imaged under the same imaging parameters in a single scanning
session. At least 10 neurons were scored from each group per experiment
over a total of three independent culture experiments. Scanned images
were analyzed using the Leica confocal software by recording fluores-
cence intensities over line profiles, which were superimposed directly on
the stained neurites. At least 40 data points were collected per group per
experiment.
In vivo injections of AAV viruses.Wepreviously described the injection
of AAV virions in the spinal parenchyma of mice in detail (Tappe et al.,
2006) (for more details, see Nature Protocols On-line). Briefly, adult
micewere anesthetizedwith fentanyl/medetomidine/midazolam (4:6:16;
0.7 l/g, i.p.) and 300 nl of a 2:1 mixture of AAV viral stocks with 20%
Mannitol containing 1.2 107 virionswere infused four times bilaterally
(two times on each side) directly into the spinal parenchyma of spinal
segments L3–L5 at a rate of 60 nl/min using amicroprocessor-controlled
minipump (World Precision Instruments, Sarasota, FL). These parame-
ters yield a selective expression of proteins at the desired levels in spinal
dorsal horn over 2–3 mm along the rostrocaudal axis without significant
spread into the ventral horn. Mice were allowed to recover for 3 weeks
before commencing behavioral analysis. At the end of the behavioral
experiments, mice were killed, and the locus and time course of AAV-
induced gene expression was monitored by EGFP fluorescence and im-
munohistochemistry using anti-HA antibodies on spinal sections.
Animal handling and nociceptive testing. All animal usage procedures
were in accordance with ethical guidelines laid down by the local govern-
ing body (Regierungspra¨sidiumKarlsruhe, Karlsruhe, Germany). All be-
havioral measurements were done in awake, unrestrained, age-matched
adult (3 months old) male C57BL/6 mice. The nociceptive tail-flick
reflex was evoked by noxious heat applied via an infrared light source
(Ugo Basile, Comerio, Italy) with a sensitivity of 0.1 s as described pre-
viously (Kolhekar et al., 1993). WIN 55,212-2 (2 mg/kg body weight) or
vehicle (50% DMSO) was injected intraperitoneally in mice, and tail-
flick latency was recorded after 1 h.
Immunohistochemistry on mouse spinal cord and dorsal root ganglion,
illustrations, and densitometry. Immunohistochemistry was performed as
described in detail previously (Hartmann et al., 2004). Briefly, animals
were perfused with 0.1 M PBS and 4% PFA. Spinal cords and dorsal root
ganglia (DRGs) were isolated and postfixed for up to 16 h in 4% PFA.
Free-floating sections of rat spinal cord (100m, vibratome) andmouse
spinal cord (50m, vibratome)were brieflymicrowaved in 10mMcitrate
buffer (18mM citric acid and 8.2mM sodiumcitrate) for antigen retrieval.
Immunohistochemistry was then performed using an anti-GASP1 anti-
body (Whistler et al., 2002), a rabbit anti-CB1 antibody (Cayman Chem-
icals), a goat anti-CB1 antibody (KenMackie, University ofWashington,
Seattle, WA), or mouse anti-HA tag (Babco, Berkley, CA) with the cor-
responding biotinylated secondary antibodies and standard reagent kits
(Vectastain Elite ABC kit; Vector Laboratories, Burlingame, CA).
Bright-field images were taken using a cooled CCD camera (Leica)
under similar illumination conditions. Staining intensity per unit area
was measured densitometrically (Scion NIH Image software, version 
4.0.2) over selected areas using unstained areas within the same section
for background correction as described previously (Dreyer et al., 2003).
Data was averaged from at least five areas per section and at least three
sections per mouse. Frozen DRG sections (16 m, cryostat) were pro-
cessed for immunofluorescence analysis using anti-GASP1 antibody
(Whistler et al., 2002) and anti-CB1 antibody (Cayman Chemical), as
described in detail previously (Dreyer et al., 2003). TRITC-conjugated
isolectin-B4 (IB4) was used to colabel nonpeptidergic nociceptive neu-
rons (Dreyer et al., 2003).
Receptor autoradiography onmouse spinal cord.After behavioral exper-
iments,micewere killed usingCO2, and the spinal cords segments L4–L6
were rapidly extracted and frozen on dry ice. Cryosections (16m) were
incubated with 10 nM 3H-CP-55940 (2-[(1R,2R,5R)-5-hydroxy-2-(3-
hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol) (PerkinElmer,
Wellesley, MA) for 2.5 h at 37°C and processed for autoradiography as
described in detail previously (Rubino et al., 2005). Autoradiograms
were generated by the incubation of tritium-sensitive film (Hyperfilm-
3H; GE Healthcare, Piscataway, NJ) with the sections for 7 d. The signal
intensity was determined by measuring gray levels using an image anal-
ysis system (Dual ScannerArtixscan 1800F and IMAGE-PRO-PLUS soft-
ware) in the linear range after subtracting the background density.
Data analysis and statistics. All data are presented as mean  SEM.
ANOVA for randommeasures was performed followed by post hoc Fish-
er’s test to determine statistically significant differences. p  0.05 was
considered significant.
Results
CB1 interacts physically with the C-terminal region of GASP1
GASP1 has been described to interact with several GPCRs har-
boring “FR” amino acids in their C terminus (Simonin et al.,
2004). Because this sequence is present in the C terminus of CB1
(9th and 10th amino acids after the seventh transmembrane: . . .
RSKDLRHAFR), we first addressed whether GASP1 could inter-
act with CB1. HEK293 cells were cotransfected with N-terminally
HA-tagged CB1 and N-terminally GFP-tagged GASP1. In trans-
fected HEK293 cells as well as in brain lysates, we observed a
prominent expression of full-length CB1 (60 kDa) and only a
low level of expression of an 45 kDa isoform (a putative
N-terminal splice variant) (Shire et al., 1995) (supplemental Fig.
1, available at www.jneurosci.org as supplemental material). CB1
could be coimmunoprecipitated with GASP1 using the anti-GFP
antibody (Fig. 1A), and, conversely, an anti-HA antibody could
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immunoprecipitate GFP–GASP1 (Fig.
1B). An HA-tagged fragment of GASP1
corresponding to the C-terminal 497 resi-
dues of GASP1 (called cGASP1 hence-
forth) (Whistler et al., 2002) was cotrans-
fected with GFP-tagged CB1. CB1 could be
coimmunoprecipitated with cGASP1 with
the anti-HA antibody (Fig. 1C), and
cGASP1 was coimmunoprecipitated with
CB1 using an anti-GFP antibody (Fig.
1D). These results show that heterolo-
gously coexpressed GASP1 and CB1 phys-
ically interact with each other and that the
C terminus of GASP1 is sufficient to me-
diate this interaction.
Previous studies have shown that a
mutant CB1 receptor lacking the last 14
residues does not internalize in HEK293
cells, whereas a mutant lacking the last 10
residues does (Hsieh et al., 1999). Particu-
larly, the amino acids V460 andV464 have
been implicated in mediating agonist-
induced internalization of CB1 receptors
(Hsieh et al., 1999). To address whether
structural determinants of CB1 internal-
ization are related to CB1–GASP1 interac-
tions, we cotransfected constructs encod-
ing HA-epitope-tagged CB1 mutants
V460Z orV464Z (Fig. 1E) with cGASP1 in
HEK293 cells. Using anti-HA antibody,
both CB1 mutants could be coimmuno-
precipitated with cGASP1 (Fig. 1E), indi-
cating that the motifs required for CB1
internalization do not play a role in the
CB1–GASP1 interaction.
In cell lysates of the EGFP–CB1-ex-
pressing cell line, an anti-GFP antibody could
coimmunoprecipitate endogenous full-
length GASP1 (250 kDa) as well as its 110
kDaproteolyticproduct(Fig.1F, leftcolumn),
suggesting that overexpression of GASP1 is
not required for interaction with CB1.
Interaction between CB1 and GASP1 in
the nervous system in vivo
To determine whether CB1 can interact
with GASP1 in vivo, we immunoprecipi-
tated endogenous CB1 from rat brain ly-
sates and performedWestern blot analysis
on the immunoprecipitates using an anti-
GASP1 polyclonal antibody, which has
been characterized previously (Bartlett et
al., 2005). Immunoreactive proteins of
sizes expected for endogenous GASP1,
250 and 110 kDa, coprecipitated with CB1
(Fig. 1F), indicating that CB1 and GASP1
expressed endogenously in the nervous
system interact with one other. Similar re-
sults were obtained from lysates of brains derived fromwild-type
mice but not from lysates derived from brains of CB1
/ mice,
demonstrating that both bands corresponding to GASP1 are co-
immunoprecipitated in a CB1-dependentmanner (supplemental
Fig. 2, available at www.jneurosci.org as supplemental material).
Agonist-induced trafficking of EGFP—CB1monitored in
HEK293 cells
To visualize agonist-induced internalization of CB1 receptors
and its modulation by potential interacting partner proteins, we
generated HEK293 cell lines stably expressing CB1 receptors
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is coimmunoprecipitated with GFP-tagged GASP1 using an anti-GFP1 antibody. B, GFP-tagged GASP1 is coimmunoprecipitated
with HA-tagged CB1 using an anti-HA antibody. C, D, Coimmunoprecipitation of an HA-tagged mutant of GASP1 comprising the
C-terminal 467 amino acids of GASP1 (cGASP1) and GFP-tagged CB1 using an anti-HA antibody (C) or an anti-GFP antibody (D). E,
GFP-tagged cGASP1 coimmunoprecipitatedwithHA-tagged internalization-deficientmutants of CB1, V460Z (1), andV464Z (2).F,
Endogenous GASP1 can be coimmunoprecipitated with CB1 in an HEK293 cell line stably expressing GFP–CB1 using an anti-GFP
antibody (left panels). Similarly, endogenous GASP1 can be coimmunoprecipitatedwith native CB1 from rat brain lysates using an
anti-CB1 antibody, as shown in the left. Specificity of this interaction is shown with a control coimmunoprecipitation using
anti-GFP antibody (right).
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N-terminally tagged with GFP. A cell line demonstrating moder-
ate levels of GFP–CB1 expression uniformly in90% of cells was
selected for additional analysis (Fig. 2A). To prevent confound-
ing the analysis of agonist-induced CB1 trafficking by CB1 syn-
thesized de novo during the experiment, all experiments were
performed in the acute presence of a protein synthesis inhibitor,
cycloheximide, which clearly revealed the pool ofGFP–CB1 in the
vicinity of the cell surface (Fig. 2A, middle, right). Our results
differ from that of Leterrier et al. (2004) over this point, a discrep-
ancy that could be explained on the basis of differences caused by
levels and mode of expression (transient vs stable transfection)
and the location of the EGFP tag [N-terminal here vs C-terminal
tag used by Leterrier et al. (2004)]. We then characterized the
time course and nature of GFP–CB1 internalization and traffick-
ing during exposure to a CB1/CB2 agonist, WIN 55,122-2 (100
nM). Confocal analysis revealed that exposure toWIN over short
periods of time (5–30 min) led to rapid internalization that was
obvious within 5 min and marked starting with a 30 min expo-
sure (Fig. 2B, top row, arrowheads). Termination of agonist ex-
posure at 5 or 30 min led to a near complete recycling of the
internalized receptors to the cell membrane within 60 min (Fig.
2B, bottom row, arrows). In contrast, after exposure toWINover
longer periods (60–90 min), the internal-
ized receptors did not recycle appreciably
back to the cell surface when tested at 60
min after termination of agonist exposure
(Fig. 2B, bottom row, arrowheads). In-
deed, endocytotic vesicles containing
EGFP–CB1 after a 60 min exposure to
WIN primarily colocalized with a lysoso-
mal marker, Lyso-tracker (Fig. 2C), show-
ing that CB1 was sorted into lysosomes af-
ter prolonged agonist exposure. Similar
results were obtained after visualizing the
trafficking of Flag-tagged CB1 in HEK293
cells (supplemental Fig. 3, available at
www.jneurosci.org as supplemental mate-
rial). Furthermore, our results are similar
to a previous report on expression of un-
tagged CB1 in AtT20 cells (Hsieh et al.,
1999), thereby indicating that the EGFP–
CB1-expressing stable cell line used here
reliably reproduces aspects of wild-type
CB1 receptor trafficking and can be used
for addressing underlying molecular
mechanisms.
cGASP1modulates trafficking of
EGFP–CB1 during agonist exposure in
HEK293 cells
Previous studies have established that a
fragment corresponding to theC-terminal
497 residues of GASP1 (cGASP1) com-
petes with the binding of full-length
GASP1 to GPCRs and can be therefore
used as a dominant-negative tool to probe
the functional relevance of GASP1–GPCR
interactions (Whistler et al., 2002; Simo-
nin et al., 2004; Bartlett et al., 2005). We
therefore transfected the EGFP–CB1 stable
cell line withHA-tagged cGASP1 or a con-
trol vector and compared WIN-induced
internalization and recycling. The basal
levels and pattern of distribution of EGFP–CB1 was comparable
in vector-transfected cells and cGASP1-transfected cells (Fig. 3A,
left column, 0 min). After a 30 or 90 min exposure to WIN, both
vector-transfected cells and cGASP1-transfected cells showed in-
ternalization of EGFP–CB1, which was similar to that observed in
untransfected cells (Fig. 3A, arrowheads). We then studied recy-
cling of EGFP–CB1 to the cell surface at 60 min after termination
of varying periods of exposure to WIN. Like untransfected cells
(Fig. 2 above), vector-transfected cells and cGASP1-trasfected
cells showed recovery of a substantial proportion of internalized
receptors at the cell surface when cells had been exposed to WIN
for 30 min (Fig. 2B, left panels, arrows). Consistent with our
results from untransfected cells (Fig. 2 above), vector-transfected
cells exposed to WIN for 90 min showed very little recovery of
EGFP–CB1 at 60 min after termination agonist treatment (Fig.
3B, top middle, arrowhead). In striking contrast, cGASP1-
expressing cells demonstrated substantial recovery of EGFP–CB1
to the cell surface under the same conditions (Fig. 3B, bottom
middle, arrows). Because cGASP1 expression did not seem to
alter agonist-induced internalization (Fig. 3A above), the in-
creased recovery of EGFP–CB1 at the cell surface likely reflects
increased recycling of internalized receptors back to the cell sur-
5 min INT 15 min INT 30 min INT 60 min INT 90 min INT
5 min INT + 1h RC 15 min INT + 1h RC 30 min INT + 1h RC 60 min INT + 1h RC 90 min INT + 1h RC
IN
T
WIN  (100 nM)B
EGFP-CB1 Lyso-tracker dye overlay
WIN  (100 nM), 60 min internalization
C
IN
T 
+ 
R
C
0 min0 min0 min
Cycloheximide (40 µM)
without
Cycloheximide
A
Figure 2. Agonist-dependent internalization and lysosomal degradation of CB1 in a stable cell line expressing N-terminally
EGFP-tagged CB1 demonstratedwith confocal imaging.A, HEK293 cells stably expressing EGFP–CB1 untreated cells (left) and cells
treated for 1 hwith 40M cycloheximide (middle, right). 0min indicates basal state before agonist exposure. Scale bars, 10m.
B, Treatment with a synthetic cannabinoid agonist, WIN 55,212-2 (WIN; 100 nM) for varying periods (5–90 min) leads to inter-
nalization of EGFP–CB1 (INT; indicated by arrowheads). Additional incubation of cells for 1 h after termination of agonist exposure
to allow recycling to the cell surface (RC) leads to recycling after agonist exposure over 5–10 min (arrows) but not after agonist
exposureover 60–90min (arrows).Whitedashed lines indicate thepositionof the cellmembrane.C, Endocytic vesicles containing
EGFP–CB1 after an agonist exposure of 60 min colocalize with a lysosomal marker, Lyso-tracker dye (yellow puncta in overlay).
Scale bars, 3m.
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face. These results suggest that, in the pres-
ence of cGASP1, degradation of CB1 in-
duced by long-term agonist exposure is
reduced and recycling to cell surface is
enhanced.
Quantitative estimation of cell surface
CB1 expression in the presence
of cGASP1
To consolidate these observations via an
independent and quantitative method of
estimation, we used an AP-based assay
(Swiercz et al., 2004) for quantifying cell
surface expression of heterologously ex-
pressed CB1. Before agonist exposure
(basal), the level of CB1 expression at the
cell membrane in the acute presence of cy-
cloheximide was similar in cells trans-
fectedwithCB1 plus vector and cells trans-
fected with CB1 plus GFP-tagged cGASP1
(Fig. 3C). During a 90 min exposure to
WIN, cell surface expression of CB1
dropped significantly in cells transfected
with CB1 plus vector (19  1% of basal
levels) (Fig. 3D, white bar), as well as in
Figure 3. A dominant-negative mutant of GASP1 attenuates recycling of EGFP–CB1 without affecting surface expression or
WIN-induced internalization. All experiments were done after acute (1 h) pretreatment with cycloheximide (40M). The EGFP–
CB1 stable cell line was transfected with an HA-tagged dominant-negative mutant of GASP1 (cGASP1–HA) or empty vector in A
and B. A, Vector-transfected and cGASP1–HA-transfected cells show internalization of EGFP–CB1 (arrowheads; INT) after treat-
4
mentwithWIN (100nM) for 30 or 90min.B, After termination
of a 30 min WIN exposure, incubation of treated cells for 1 h
(RC) led to recycling of EGFP–CB1 to the cell membrane (ar-
rows) in vector-transfected cells and cGASP1–HA-transfected
cells. In contrast, during incubation of treated cells for 1 h (RC)
after termination of a 90 min WIN exposure, cGASP1–HA-
transfected cells show recycling of EGFP–CB1 to the cellmem-
brane (arrows), whereas vector-transfected cells do not (ar-
rowheads; white dashed line indicates position of the cell
membrane). Panels at the right show expression of HA-
tagged cGASP1 via anti-HA immunoreactivity. Scale bars: A,
B, 3 m. C, D, A quantitative cell surface expression assay
based on activity of AP was performed on COS7 cells trans-
fectedwith N-terminally FLAG-tagged CB1 plus empty vector,
FLAG-tagged CB1 plus GFP-tagged cGASP, or empty vector
alone (for details, see Materials and Methods). AP activity (a
measure of CB1 expression at the cell membrane) was not
affected by expression of cGASP in the naive state (C). During
a 90 min exposure to WIN (100 nM), AP activity decreased in
both treatment groups, indicating internalization (INT; white
and black bars). D, Additional incubation of cells for 1 h after
termination of a 90 min WIN exposure to allow recycling to
the cell surface (RC) leads to recycling in cells expressing CB1
plus cGASP1 (dark gray bar) but not in cells expressing CB1
plus vector (light gray bar). *p 0.05, ANOVA followed by
Fisher’s test. n 3 independent culture experiments each in
duplicates in all panels.E, The stability of internalized CB1was
assessed using a biotin protection assay. HEK293 cells stably
expressing CB1 were biotinylated and treated with 1MWIN
55,212-2 for the times indicated before stripping with
membrane-impermeant reducing agent. The “protected” in-
ternalized receptor pool was then immunoprecipitated and
visualized. CB1 degrades after internalization by WIN
55,212-2, which can be reduced by adding the proteolysis
inhibitors (PI). F, The stability of the internalized CB1 was as-
sessed in cells stably expressing CB1 alone or expressing CB1
and overexpressing cGASP using a biotin protection assay.
Overexpression of cGASP100-fold over endogenous GASP
delayed degradation of the CB1. S, Stripped; NT, nontreated.
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cGASP-expressing cells (20  5% of control levels) (Fig. 3D,
black bar), indicating that agonist-induced internalization was
not affected by cGASP expression (F 0.0099; p 0.924).When
cells were tested for recycling at 60min after a 90min exposure to
WIN, cells transfected with CB1 plus vector failed to demonstrate
significant recycling to the cell surface (25  5% of basal; F 
1.731; p 0.236 compared with internalization alone) (Fig. 3D,
light gray bar). In striking contrast, cells expressing cGASP dem-
onstrated significant recovery ofCB1 expression at the cell surface
(51 8% of control; F 7.834; p 0.031 compared with inter-
nalization alone) (Fig. 3D, dark gray bar). This was significantly
higher than recovery in vector-transfected cells (F 11.329; p
0.015). Thus, these results verify that cGASP1 promotes recycling
of internalized CB1 to the cell surface.
We then used a biotin protection assay to assess the effects of
cGASP1 on the stability of internalizedCB1 in cells stably express-
ing CB1. Considerable degradation was found in the internalized
pool of CB1 after prolonged treatment
with WIN (Fig. 3D), which was reduced
during treatment with proteolysis inhibi-
tors (Fig. 3D). Similarly, when GFP–
cGASP was coexpressed with CB1 at levels
100-fold over endogenousGASP (data not
shown), the stability of internalized CB1
was remarkably enhanced (Fig. 3E). Thus,
the overexpression of dominant-negative
cGASP delayed degradation of the CB1,
suggesting that postendocytic sorting of
the CB1 to the lysosomal degradation
pathway is mediated by GASP.
Trafficking of native CB1 in
spinal neurons
To place these findings in a more physio-
logical context, we then studied CB1 traf-
ficking in primary spinal neurons, which
were cultured from rat embryonic spinal
cord and allowed to mature for 3 weeks in
vitro. In cultures derived thus, a majority
of large neuronswith large, arborized neu-
rites demonstrated intense immunoreac-
tivity for CB1 (data not shown). A large
number of small neurons with very short
processes (Fig. 4A, arrowheads) demon-
strated only very weak CB1 immunoreac-
tivity restricted to the cell soma and were
not taken into account for this analysis.
Cell surface CB1 was selectively ana-
lyzed using a standard surface staining
protocol, and neurofilament 200, a pro-
tein widely and stably expressed in neu-
rons, served as an internal control for the
integrity and state of the neuron (typical
examples are shown in Fig. 4A). Laser
scanning confocal microscopy in the se-
quential mode enabled quantitative as-
sessment of agonist-induced changes in
surface staining for CB1 as a function of
total neurofilament 200 expression in a
large population of neurites in the naive
state (basal) and at different time points
after exposure to WIN (Fig. 4B).
In the naive state, surface labeling of
CB1 yielded strong staining in neurites (TRITC channel in Fig.
4A, top). During a 6 h exposure to WIN, there was no change in
the surface labeling of CB1 (data not shown), and a 12 h exposure
only led to a trend of a decrease in surface CB1 expression in
neuronal neurites (Fig. 4A,B). In contrast, when neurons were
treated for 24 h with WIN, surface expression of CB1 in neurites
dropped by nearly 50% (typical examples in Fig. 4A, compare
purple overlay at 24 h with pink overlay in the basal state; B, left)
(F 14.532; p 0.004). A similar course ofWIN-induced inter-
nalization was observed after analyzing cell surface expression of
CB1 over the soma of the treated neurons (Fig. 4B, right) (F 
7.932; p  0.023). Protracted exposure to WIN for 48 h did not
increase in the level of WIN-induced downregulation of CB1 in
neurites or soma (Fig. 4A,B) (F  22.418, p  0.001 at 48 h in
neurites; F  13.268, p  0.005 at 48 h in soma). These results
show that prolonged treatment with a cannabinoid leads to a
marked loss of endogenous CB1 from the surface of neurites of
Figure 4. Analysis of CB1 downregulation from the surface of primary cultured rat spinal cord neurons during prolonged
treatmentwithWIN (1.5M). A surface-labelingprotocolwasused to assess surface expressionof CB1 (TRITC) and stained cultures
were fixed and immunostained with an anti-neurofilament 200 (NF200) antibody (Cy5), as an internal control. All images were
taken in the same imaging conditions, and all signals were below saturation limits. A, Typical examples of confocal images
acquired in the sequential mode representing a high level of CB1 expression at the surface of spinal neurites in the naive state
(basal) andWIN-induced decrease in surface CB1 expression (12, 24, and 48 h). Line profiles on the right demonstrate the intensity
of the signals (solid lines) and background (dashed lines). B, Quantitative estimation of CB1 expression at the surface of spinal
neurites or soma as a fraction of the corresponding neurofilament 200 expression. Significant downregulation is observed after
WIN treatment for 24 or 48 h (*p 0.05, ANOVA, post hoc Fisher’s test). n 40 data points each per group. Scale bar, 40m.
Tappe-Theodor et al. • Analgesic Tolerance to Cannabinoids J. Neurosci., April 11, 2007 • 27(15):4165–4177 • 4171
primary spinal neurons, albeit with delayed kinetics compared
with CB1 expressed heterologously in HEK293 cells.
Effects of cGASP1 on trafficking of native CB1 in
spinal neurons
In Figure 1E, we showed that cGASP1 efficiently associates with
heterologously expressed CB1 in HEK293 cells. To ascertain that
cGASP1 can also interact with endogenous CB1 in neurons, we
transduced cultured spinal neurons with SFV virions expressing
HA-tagged cGASP1. Indeed, an anti-HA antibody coimmuno-
precipitated endogenous CB1 with HA–cGASP1 in neurons
transduced with SFV–HA–cGASP1 but not in naive neurons
(Fig. 5A). Interestingly, in contrast to the brain, the 45 kDa form
of CB1 corresponding to a putative N-terminal splice variant of
CB1 (Shire et al., 1995) was found to be predominantly expressed
in cultured spinal neurons, and the 60 kDa formwas found at low
levels only (supplemental Fig. 1, available at www.jneurosci.org
as supplemental material). We then addressed whether GASP1
contributes to downregulation of CB1 at the surface of neurites
after prolonged agonist exposure in spinal neurons. To enable
long-lasting expression of cGASP1 in cultured spinal neurons, we
generated recombinant chimeric adeno-associated Virus-1/2
virions (rAAV1/2) (During et al., 2003) expressing HA-tagged
cGASP1 (AAV–cGASP1). AAV1/2 virions expressing EGFP
served as controls (see below). Transduction of AAV–
cGASP1–HA virions led to a rapid and readily detectable expres-
sion ofHA-tagged cGASP1 in a large number of exposed neurons
within 12 h (see below).
Primary spinal neurons expressing AAV–EGFP1 or AAV–
cGASP1–HA were visualized via EGFP fluorescence or anti-HA
immunoreactivity (Fig. 5B,C, left, green fluorescence). The fate
of internalized native CB1 receptors in these neurons after WIN
exposure was monitored in triple-labeling experiments via con-
focal microscopy (Fig. 5B). Scanning was done in sequential
mode to absolutely rule out bleed-through of signals across chan-
nels. Similar to naive, untransduced neurons (Fig. 4, above), neu-
rons transducedwith AAV–EGFP showed a significant loss of cell
surface CB1 in neurites after a 24 h exposure to WIN (compare
Figure 5. A dominant-negative mutant of GASP1 (cGASP1) attenuates WIN-induced downregulation of CB1 from the surface of primary cultured rat spinal neurons. A surface-labeling protocol
wasused to assess surface expressionof CB1 (TRITC), and stained cultureswere fixedand immunostainedwith ananti-neurofilament 200 (NF200) antibody (Cy5) tonormalize CB1 immunoreactivity.
A, HA-tagged cGASP1 was virally transduced in cultured spinal neurons. An anti-HA antibody could coimmunoprecipitate cGASP1 and endogenous CB1 from lysates of spinal neurons. IP,
Immunoprecipitation; IB, immunoblot. B, EGFP was overexpressed in cultured spinal neurons via an AAV vector. Typical examples of confocal images representing a high level of CB1 expression at
the surface of spinal neurites in the naive state (basal) and decrease in surface CB1 expression after a 24 h exposure to WIN (1.5M) are shown. C, HA-tagged cGASP1 was overexpressed in spinal
neurons via an AAV vector and was recognized via anti-HA immunofluorescence using FITC-labeled antibodies. Typical examples of confocal images representing levels of CB1 expression at the
surface of spinal neurites in the naive state (basal) or after a 24 h exposure to WIN (1.5M) are shown. Note that cGASP1-expressing neurons do not show amarked downregulation of CB1 during
WIN treatment, as EGFP-expressing neurons do (B). D, Quantitative estimation of CB1 expression at the surface of spinal neurites as a fraction of the corresponding neurofilament 200 expression.
Significant downregulation is observed after a 24 hWIN treatment over basal in EGFP-expressing neurites but not in cGASP1-expressing neurites. n 40 data points per group. *p 0.05, ANOVA,
post hoc Fisher’s test. n.s., Nonsignificant. Scale bars: B, C, 40m.
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overlay at 24 h with overlay in the basal state in typical examples
in Fig. 5B; quantification is shown in D) (F  62.11; p  0.001
over basal state). In contrast, neurites of neurons transducedwith
AAV–cGASP1 demonstrated only a minor decrease in surface
expression of CB1 after a 24 h exposure toWIN (compare overlay
at 24 h in cGASP1-expressing neurites with overlay in the basal
state in typical examples in Fig. 5B), which did not reach statisti-
cal significance (F  2.253; p  0.16 over basal state) (Fig. 5D).
These results show that interfering with the GASP1–CB1 interac-
tions in primary spinal neurons prevented
cannabinoid-induced downregulation of
CB1 from the surface of neurites.
Expression of GASP1 in the spinal
sensorimotor circuit processing pain
Because nothing has been reported so far
on the expression GASP1 protein in the
regions of the nervous system that are im-
portant in processing pain, we performed
immunohistochemistry with an anti-
GASP1 antibody (Bartlett et al., 2005) on
sections of the spinal cord and DRG of
mice.
Immunoreactivity for GASP1 was dis-
tributed throughout the spinal cord, and a
few spinal motor neurons in laminas VIII
and IX demonstrated strong immunore-
activity for GASP1 (Fig. 6A, arrow).
GASP1 immunoreactivity was most
prominent in the spinal dorsal horn, par-
ticularly in the superficial spinal laminas,
which are important in nociceptive pro-
cessing (Fig. 6A, arrowheads). Of note, we
observed that immunoreactivity for CB1 is
also particularly dense in the superficial
lamina I of the spinal dorsal horn (Fig. 6B,
arrowhead), consistent with previous re-
ports (Salio et al., 2002). In addition to cell
bodies in the superficial laminas, a large
part of the GASP1 immunoreactivity was
found in the neuropil, reflecting that spi-
nal terminals of nociceptive primary affer-
ent fibers, which densely innervate this re-
gion, could harbor cGASP1. Consistent
with the above, DRG sections demon-
strated vivid GASP1 immunoreactivity in
populations of neurons (Fig. 6C). To de-
termine whether CB1 and GASP1 colocal-
ize in DRG neurons, we performed cola-
beling with a goat anti-CB1 antibody,
which does not demonstrate immunore-
activity in CB1
/mice (data not shown).
Dual-immunofluorescence analysis re-
vealed a high level of overlap between the
expression of CB1 and GASP1 in DRG
neurons (Fig. 6C).
To address whether nociceptive neu-
rons expressGASP1,we costained sections
with IB4–TRITC, which labels the non-
peptidergic population of small-diameter
nociceptive neurons (Nagy and Hunt,
1982). Nearly all IB4–TRITC-positive
neurons were GASP1 immunoreactive
(Fig. 6D, yellow in overlay), but also some other cell types, par-
ticularly with large diameters, express GASP1 (Fig. 6D). Several
IB4–TRITC-positive neurons also demonstrated anti-CB1 im-
munoreactivity (Fig. 6D), showing that nociceptive neurons can
express CB1 and GASP1.
We then addressed whether the expression levels or patterns
of GASP1 are regulated over the periods of sustained exposure to
cannabinoids. Mice were repeatedly administered with WIN in-
traperitoneally (2 mg/kg body weight) over a period of 7 d. Mice
A anti-GASP1 anti-CB1B
anti-GASP1 anti-IB4 overlay
D
anti-CB1 anti-IB4 overlay
anti-CB1 anti-GASP overlayC
Figure 6. Pattern of GASP1 immunoreactivity overmouse spinal sensorimotor circuits processing nociceptive inputs.A, GASP1
immunoreactivity is found throughout the spinal cord and is particularly abundant in superficial laminas of the spinal dorsal horn
(arrowheads; magnified in panel at the right) and in spinal motor neurons (arrow). B, Immunoreactivity for CB1 is also found
throughout the spinal dorsal horn and is also dense in themost superficial lamina.C, Dual-immunofluorescence experiments using
a rabbit anti-GASP1 antibody and a goat anti-CB1 antibody on sections of DRG reveal a high degree of colocalization between
endogenous GASP1 and native CB1. D, Immunofluorescence labeling of DRG sections shows that GASP1 as well as CB1 are widely
expressed in the DRG, including nonpeptidergic nociceptive neurons that are identified via staining with TRITC-labeled IB4. Scale
bars: A, B, 200m; C, D, 40m.
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injected with saline in a similar manner served as controls. Im-
munohistochemistry failed to reveal any obvious changes in the
expression of GASP1 in the spinal cords or DRG of mice with
long-term cannabinoid treatment over vehicle-treated mice
(data not shown). Furthermore, densitometric quantification of
GASP1 immunoreactivity over superficial spinal laminas failed to
reveal a significant difference between vehicle-treated and WIN-
treated mice (26.4  5 and 30.9  4.3 optical density units, re-
spectively; F 0.461; p 0.516).
In vivo analysis of agonist-induced CB1 downregulation and
analgesic tolerance
To study the relevance of our in vitro observations to analgesic
tolerance to cannabinoids in vivo, we first established an assay
system consisting of two important parameters. First, we ana-
lyzed whether repeated systemic administration of WIN leads to
analgesic tolerance at the level of the spinal cord in mice, and,
second, we assessed whether this process is directly associated
with downregulation of CB1 in the spinal cords of the same ani-
mals. Because we focused on spinal mechanisms in this study, we
chose to analyze the latency of tail withdrawal after application of
noxious heat (tail-flick reflex). The tail-flick reflex is a nociceptive
withdrawal reflex that is elicited via spinal circuitry and does not
require supraspinal pain centers (Kolhekar et al., 1993). Intra-
peritoneal administration of WIN (2 mg/kg) acutely produced a
more than fourfold increase in the latency of tail-flick to radiant
heat (i.e., analgesia) on the first, second, third, and fourth day of
WIN administration (Fig. 7) (F 137.947, p 0.001 on first day
compared with the basal latency; F 22.648, p 0.003 on day 2;
F 36.789, p 0.001 onday 3;F 74.05, p 0.001 onday 4;F
44.547, p  0.001 on day 5; F  5.196, p  0.044 on day 6; F 
14.366, p  0.003 on day 7; F  16.036, p  0.002 on day 8
compared with the basal latencies, respectively). Starting from
day 5 of WIN administration, WIN-induced analgesia decreased
significantly by50% (F 14.299, p 0.009 on day 6 compared
with analgesia achieved on day 1; F 13.728, p 0.010 on day 8
compared with day 1) (Fig. 7). The spinal cords of chronically
WIN- or vehicle-treated mice were then processed for receptor
autoradiography, a method that is very sensitive in detecting re-
ceptor downregulation in small quantities of tissue. Autoradiog-
raphy with 3H-CP-55,940, a high-affinity CB1 agonist (Rubino et
al., 2003), revealed a significant decrease in the density of canna-
binoid binding sites in the spinal dorsal horn of spinal cords of
mice treated chronically withWIN compared with mice that had
received the vehicle (13.07  1.55 reduction in 3H-CP-55940
binding intensity in theWIN group over vehicle; F 33.623; p
0.001). Thus, repeated systemic administration of a cannabinoid
produced tolerance to its antinociceptive effects at the level of the
spinal cord and led to concurrent downregulation of CB1 in the
spinal cord.
Effects of cGASP1 on agonist-induced CB1 downregulation
and analgesic tolerance in vivo
To test the functional significance of the CB1–GASP1 interaction
in this process in vivo, we sought to perturb this interaction by
overexpressing cGASP1 selectively in the superficial spinal lami-
nas of mice. Toward this end, rAAV1/2–cGASP1 virions were
injected directly into the spinal parenchyma of adult mice. We
previously demonstrated that direct intraparenchymal injection
of AAV1/2 virions in the spinal dorsal horn leads to long-lasting
expression of desired proteins selectively in the spinal dorsal horn
in vivowithout producing any toxicity (Tappe et al., 2006). In the
present study, intraparenchymal injection of AAV–cGASP1 led
to a clearly detectable expression of HA-tagged cGASP1, which
was restricted to the spinal dorsal horn, as judged via anti-HA
immunohistochemistry (Fig. 8A). A group of control mice in-
jected spinally with rAAV1/2 virions expressing EGFP served as
controls (Fig. 8A). Injected mice did not show any evidence of
tissue toxicity or gliosis, as judged via Nissl staining and immu-
nostaining with a neuronal marker (anti-neuronal-specific nu-
clear protein) or immunostaining with anti-GFAP, respectively,
at 2–3 weeks after injection (supplemental Fig. 4, available at
www.jneurosci.org as supplemental material).
We then divided cGASP-injected mice and EGFP-injected
mice into two groups each: one group was injected with WIN
intraperitoneally every day for 14 d, whereas the other (control)
group received vehicle injections. Neither EGFP-injected nor
cGASP1-injected mice receiving vehicle treatment showed any
significant changes in baseline tail-flick latency over the entire
period of evaluation. TreatmentwithWINproduced a significant
increase in tail-flick latency in EGFP-injected mice as well as
cGASP1-injected mice over the first 2 d of treatment (Fig. 8B).
Although the degree ofWIN-induced analgesia was unexpectedly
observed to be significantly lower in cGASP1-expressing mice
over EGFP-expressing mice on the first day of treatment (F 
9.438; p 0.01), differences were not apparent at days 2–4. Im-
portantly, starting with day 6 and up to day 14 of treatment,
EGFP-expressing mice demonstrated a progressive decrease in
themagnitude ofWIN-induced antinociceptive effect on the tail-
flick reflex, i.e., they developed analgesic tolerance to WIN ( p
0.001 in all cases; F values were between 25.108 and 440.877 for
AAV–EGFP WIN-treated mice compared with vehicle-treated
mice from day 1 to 12). In striking contrast, cGASP1-expressing
mice did not develop any tolerance to WIN and continued to
show significant analgesia with WIN over the entire period of
analysis (Fig. 8B) ( p 0.001 in all cases; F values were between
63.758 and 732.55 for AAV–cGASP1 WIN-treated mice com-
pared with vehicle-treated mice from day 1 to 14; F 21.83, p
0.001 on day 6 compared with EGFP-expressing mice; F 
45.486, p 0.001 on day 8; F 27.074, p 0.001 on day 10; F
11.927, p  0.001 on day 12; F  100.079, p  0.001 on day 14
compared with EGFP-expressing mice, respectively).
After the termination of the behavioral analysis, autoradiog-
Figure 7. Repetitive treatment with WIN produces analgesic tolerance and CB1 downregu-
lation in the spinal cord in vivo. Intraperitoneal administration of WIN caused a significant
increase in tail-flick latency over 8 d of administration compared with vehicle. n 4 or 9 mice
per group, respectively. *p  0.05 indicates significant difference compared with vehicle-
injected mice; ANOVA, post hoc Fisher’s test.p 0.01 indicates significant difference com-
pared with WIN-injected mice at day 1; ANOVA, post hoc Fisher’s test.
4174 • J. Neurosci., April 11, 2007 • 27(15):4165–4177 Tappe-Theodor et al. • Analgesic Tolerance to Cannabinoids
raphywas performedon spinal cord sections of the tested animals
using 3H-CP-55,940. Similar to our results in uninjected mice
(Fig. 7, above), EGFP-expressing mice chronically exposed to
WIN demonstrated clearly reduced 3H-CP-55,940-binding in
the superficial dorsal horn compared with EGFP-expressing
mice, which received vehicle treatment (16.15  1.48 reduction
in 3H-CP-55940 binding intensity in the WIN group over vehi-
cle) (for a typical example, see Fig. 8C). In contrast, chronic
WIN-induced reduction in spinal 3H-CP-55,940-binding was
significantly less pronounced in cGASP1-expressing mice
(5.376  0.845 reduction in 3H-CP-55940 binding intensity in
the WIN group over vehicle; F  32.745, p  0.001 compared
with EGFP-expressing mice).
Together, these data show that downregulation of CB1 as well
as analgesic tolerance to repeated, chronic cannabinoid exposure
were markedly reduced in mice expressing cGASP1 in the spinal
dorsal horn.
Discussion
We show here that the lysosomal sorting protein, GASP1 inter-
acts with CB1 in the nervous system and mediates downregula-
tion of CB1 during protracted agonist exposure in HEK293 cells,
cultured spinal neurons, and spinal cord in vivo. We found that
GASP1 is expressed in the spinal cord and dorsal root ganglia in
cells that are important in pain processing and cannabinoid-
induced analgesia. Importantly, interfering with CB1–GASP1 in-
teractions in mouse spinal cord neurons reduced analgesic toler-
ance to cannabinoids. This study thus provides the insights into
protein interactions of CB1 and establishes their central role in
CB1 receptor trafficking and analgesic tolerance to cannabinoids
in vivo.
A key role for GASP1 in the intracellular trafficking of CB1
Protein–protein interactions constitute one of the most critical
determinants of the subcellular localization as well as the signal-
ing mechanisms of several classes of receptors, including GPCRs,
ion channels, receptor tyrosine kinases, etc. (Kim and Sheng,
2004; Sexton et al., 2006). We observed that CB1 interacts physi-
cally with theC-terminal portion of the lysosomal sorting protein
GASP-1. The CB1–GASP1 interaction did not affect the surface
localization of CB1 in naive states, i.e., in the absence of agonists,
suggesting that GASP1 does not regulate the initial targeting of
newly synthesized CB1 to its site of action in the membrane.
Furthermore, the molecular determinants of CB1–GASP1 inter-
action do not lie in thoseC-terminal amino acids of CB1 that have
been implicated in ligand-induced internalization (Hsieh et al.,
1999). This is supported by our observation that cGASP1 does
not significantly affect ligand-induced internalization but only
appears to regulate the later step of internalized CB1 recycling
back to the cell surface.
A majority of GPCRs can rapidly recycle to the cell surface
after agonist-induced internalization (Tsao and von Zastrow,
2000; von Zastrow, 2003); however, for some GPCRs, lysosomal
sorting appears to terminate signaling (Trejo et al., 1998). Con-
sistent with a previous report (Hsieh et al., 1999), we found that
CB1 demonstrates both modes of agonist-induced trafficking in
HEK293 cells: one that involves a rapid internalization and recy-
cling when receptors are exposed to the agonist over short peri-
ods, and another that involves lysosomal targeting and degrada-
tion of CB1 during prolonged agonist exposure.We observed that
interfering with the GASP1–CB1 interaction selectively affected
the fate of internalized receptors after prolonged agonist expo-
sure in HEK293 cells. Because we could coimmunoprecipitate
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GASP1 and CB1 fromHEK293 cells, spinal neurons, and brain in
the absence of exogenously administered CB1 agonists, the inter-
action between GASP1 and CB1 does not appear to strictly re-
quire prolonged agonist-induced activation of CB1. Therefore,
the differential fate of internalized receptors after short or pro-
longed exposure to the agonist is likely not determined by differ-
ential coupling to GASP1. It is possible that a prolonged expo-
sure, but not a short-term exposure, to the agonist places the
CB1–GASP1 complex in a conformation that permits sorting of
CB1 into lysosomes.
GASP1 determines the fate of native CB1 in neurons ex vivo
and in vivo
A critical question is whether the above scenario for CB1 ex-
pressed heterologously inHEK293 cells is relevant toCB1 natively
expressed in neurons. Consistent with a previous report on cul-
tured hippocampal neurons (Coutts et al., 2001), we observed in
primary cultures of spinal neurons that a downregulation of na-
tive CB1 from the dendritic surface required agonist exposure
overmuch longer periods to be evident than inHEK293 cells. It is
possible that shorter periods of exposure leads to internalization
and rapid recycling that is below the sensitivity limits of our
method of detection. Importantly, and entirely consistent with
our observations on the EGFP–CB1-expressing HEK293 cell line,
downregulation of CB1 in neurites of spinal neurons during pro-
longed agonist exposure was significantly attenuated during dis-
ruption of the CB1–GASP1 association. Thus, GASP1 is a key
mediator of the CB1 degradation after agonist exposure in
neurons.
Using receptor autoradiography, we found that chronic treat-
ment with a cannabinoid indeed downregulates binding sites for
CB1 in the spinal cord of mice and that the CB1–GASP1 interac-
tion is required for this process. Neither the level of CB1 expres-
sion on the surface of spinal neurites nor themagnitude of ligand
binding in the spinal cord was affected by cGASP1 in the absence
of the agonist. This suggests that the GASP1–CB1 interaction
does not affect the expression of endogenous CB1 in neurons per
se but selectively regulates the surface recovery of CB1 after ago-
nist exposure. Together, our comprehensive analyses from het-
erologous, ex vivo, and in vivoneuronal systems show thatGASP1
mediates degradation and downregulation of CB1 during pro-
longed or repetitive treatment with cannabinoids.
Functional relevance of CB1–GASP1 interaction to analgesic
tolerance to cannabinoids
Studies that test the applicability of results derived from traffick-
ing experiments in vitro to drug tolerance phenomena in animal
models and clinical settings are very scarce (He et al., 2002; Bar-
tlett et al., 2005).Here, we directly explored the significance of the
CB1–GASP1 interaction to the tolerance that develops to the an-
algesic effects of cannabinoids during repeated administration to
mice. The overexpression of cGASP1 in the superficial laminas
processing nociceptive inputs was sufficient to prevent tolerance
that developed toward the spinal antinociceptive effects of a can-
nabinoid during systemic administration over 6–14 d. cGASP1
also antagonized downregulation of CB1 caused by chronic can-
nabinoid administration. These results thus validate the func-
tional significance of the CB1–GASP1 interaction in the intact
nervous system and provide a crucial link between receptor
downregulation in vitro and in vivo with the complex phenome-
non of drug tolerance in an animal. However, it is important to
note that the striking effect of spinally expressed cGASP on anal-
gesic tolerance to cannabinoid treatment could be detected be-
cause we chose a nociceptive test, the tail-flick reflex, which is
mediated by the spinal nociceptive circuitry. Because cannabi-
noids induce analgesia by activating receptors at multiple ave-
nues in the pain pathway, to clinically exploit CB1–GASP1 inter-
action, it will be important to target various loci in the nervous
system and not the spinal cord alone.
Using Northern blotting and in situ hybridization, Simonin et
al. (2004) recently described the expression of GASP1mRNA in a
few organs. However, the expression of GASP1 in regions impor-
tant in pain processing was not characterized in detail.Moreover,
nothing has been reported so far on the expression GASP1 pro-
tein in nociceptive pathways. We observed strong immunoreac-
tivity for GASP1 in neurons of the DRG, including nonpeptider-
gic nociceptors, which also express CB1. In the spinal cord,
GASP1 immunoreactivity was most abundant in the superficial
laminas, consistent with a high density of CB1 in the dorsal horn,
which was revealed by binding sites for 3H-CP-55,940. We did
not detect any obvious changes in the expression levels of GASP1
protein in the spinal dorsal horn during chronic exposure to
cannabinoids in any of the mice tested. However, it might be
interesting to address whether a differential constitutive expres-
sion of GASP1 correlates with the degree to which analgesic tol-
erance develops in individual subjects, which might clarify the
clinical observation that some patients are more predisposed
than others to develop analgesic tolerance. Recent studies have
suggested that the activation of protein kinase A (PKA) and Src
tyrosine kinase, but not of protein kinase C or protein kinase G,
can reverse tolerance to some of the biological effects of the nat-
ural cannabinoid 	9-tetra hydro cannabinol, although
cannabinoid-induced analgesia was not tested (Lee et al., 2003;
Bass et al., 2004). It will be interesting to see whether PKA and
Src-induced effects involve modulation of GASP1 function.
Tolerance limits the utility of cannabinoids as well as opioids
in long-term clinical management of chronic pain disorders
(Herning et al., 1981; Pertwee, 1991; Jasinski, 1997; Jage, 2005;
Lichtman andMartin, 2005). Because we observed a requirement
for GASP1–CB1 interactions for the development of tolerance
toward the spinal antinociceptive effects of cannabinoids, the
disruption of the CB1–GASP1 interactionmay provide a basis for
improving the clinical utility of cannabinoids. In this regard, the
recombinant AAV vector that we used to selectively overexpress
cGASP1 in the spinal dorsal horn is optimized to provide a high
efficiency of transduction, stable expression in the CNS over
months, tropism for neurons, and a lack of an immune response
and toxicity (Mastakov et al., 2002; During et al., 2003). Despite
this, cGASP may not be an optimal tool because it would target
interactions of GASP1 with several other GPCRs (Heydorn et al.,
2004; Simonin et al., 2004; Bartlett et al., 2005), which may be
important in physiological pain and other biological functions.
Rather, targeting regions of CB1 that physically interact with
GASP1 via small molecules or decoy peptides may enable selec-
tively inhibiting GASP1-mediated degradation of CB1 and
thereby help to improve the magnitude and duration of
cannabinoid-induced analgesia in chronic pain states.
In summary, this study establishes a crucial functional link
between lysosomal sorting of CB1 and tolerance to cannabinoid-
induced analgesia and clarifies themolecularmechanisms under-
lying these biologically and clinically relevant phenomena.
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